DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Carcinoma, Renal Cell

Intervention: Sorafenib (Nexavar, BAY43-9006) (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Summary

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Clinical Details

Official title: Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Percentage of patients in whom the actual dose of sorafenib equaled the planned dose

Secondary outcome: Overall tolerability of treatment as measured by rate of adverse events

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age >/= 18 years

- Diagnosis of renal cell carcinoma

- Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or

disqualified from therapy with IFN/IL-2

- Patients in whom the oncologist has decide to start therapy with sorafenib.

Exclusion Criteria:

- Synonymous with contraindications to Nexavar.

Locations and Contacts

Many Locations, Poland
Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: February 2010
Last updated: June 17, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017